Last reviewed · How we verify

Cerebral cysticercosis — Treatment Landscape & Competitive Intelligence

Cerebral cysticercosis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cerebral cysticercosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Albenza ALBENDAZOLE Impax Labs Inc Anthelmintic [EPC] 1996-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Impax Labs Inc · 1 drug in Cerebral cysticercosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cerebral cysticercosis:

Cite this brief

Drug Landscape (2026). Cerebral cysticercosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cerebral-cysticercosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing